证券之星消息，10月30日化学制药板块较上一交易日下跌1.28%，翰宇药业领跌。当日上证指数报收于 3986.9，下跌0.73%。深证成指报收于13532.13，下跌1.16%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300255 | 常山药业 | 7451.52万 | 2.43% | -6875.79万 | -2.24% | -575.73万 | -0.19% | | 688759 | C必贝特 | 5872.22万 | 8.02% | 166.62万 | 0.23% | -6038.84万 | -8.25% | | 600079 | 人福医药 | 5403.96万 | 6.70% | -8584.67万 | -10.64% | ﺍﻟﻤﻮﺍﻗﻊ ﺍﻟﻤﺴﺘ 3180.72万 | 3.94% | | 603707 | 健友股份 | 4874.92万 | 14.52% | -12 ...

Summary of the Conference Call for Jianyou Co., Ltd. Company Overview - **Company**: Jianyou Co., Ltd. - **Date**: October 24, 2025 Key Points Financial Performance - Revenue for the first three quarters of 2025 decreased by 5.25% year-on-year to 3.09 billion RMB, while net profit fell by 29% to 430 million RMB, primarily due to increased sales and management expenses, especially in the U.S. market [2][3] - The total assets reached 10.3 billion RMB, with net assets attributable to shareholders at 6.75 billion RMB [3] Sales and Management Expenses - Sales expenses increased by approximately 90 million RMB, and management expenses rose by about 50 million RMB, largely due to investments in the U.S. market for large molecules and innovative drugs [4] - The company expects total revenue for the year to be between 4.2 billion and 4.4 billion RMB, with profits around 600 million to 700 million RMB [4] Raw Material and CDMO Business - The raw material segment saw a revenue decline of 37% year-on-year, with net gross profit down 40%. However, a 15% price increase is anticipated due to rising demand for high-quality raw materials [10] - CDMO business revenue decreased by 60%, but excluding certain sales impacts, it remained stable year-on-year, with future order growth expected at 25%-30% [11] Domestic and International Formulations - Domestic formulation shipments fell by 13% year-on-year, with gross profit declining over 20% due to price reductions following contract renewals [12] - International formulations performed well, with sales volume increasing by 21% and revenue up 32%, significantly driven by the U.S. market [14] Major Products and Market Competition - Three main large molecule products (White Purple, Adalimumab) maintained stable market shares, although White Purple faced pricing competition [8] - The company expects total revenue from these products to be adjusted to 65 million USD, with a net gross profit of 30 million USD for the year [9][16] Innovative Drug Development - The M22 Phase II clinical trial was completed, showing that 50% of patients could discontinue hormone treatment within six months. Discussions with the FDA for Phase III are ongoing [7] - The company plans to launch three insulin products in collaboration with Dongbao, targeting a 15%-20% market share within 4-6 quarters [17] R&D and Future Strategy - R&D expenses increased by 45 million RMB year-on-year, with five new projects initiated in the peptide large molecule field [6] - The company aims for large molecule drugs to account for over 60% of revenue by 2030, with a focus on expanding in the U.S. and European markets [4][22] Market Environment and Regulatory Changes - The FDA's easing of clinical requirements for biosimilars is expected to intensify competition but also provide opportunities for efficient companies [21] - The company is adapting its strategy to increase the proportion of self-completed projects in the large molecule field, aiming for 40%-50% by the end of 2025 [23] Challenges and Opportunities - The company faces challenges from pricing pressures and competition but is optimistic about future growth driven by innovative drug development and market expansion [31][33] - The strategic focus includes enhancing R&D capabilities and leveraging regulatory changes to improve market positioning [32] Conclusion - Jianyou Co., Ltd. is navigating a challenging market environment with a strategic focus on innovation and expansion in large molecule drugs, while addressing cost pressures and competition effectively. The company is well-positioned for future growth, with a clear roadmap for product development and market penetration.

智通财经APP讯，健友股份(603707.SH)披露2025年第三季度报告，公司前三季度实现营收29.26亿元， 同比下降5.25%;归母净利润4.29亿元，同比下降29.11%;扣非净利润3.84亿元，同比下降29.95%;基本每 股收益0.27元。 ...

Group 1 - The core point of the article is that Jianyou Co., Ltd. (SH 603707) held its 15th meeting of the 5th board of directors on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - For the year 2024, Jianyou Co., Ltd.'s revenue composition is 99.85% from the pharmaceutical manufacturing industry and 0.15% from other businesses [1] - As of the report date, Jianyou Co., Ltd. has a market capitalization of 15.6 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (健友股份), announced that its subsidiary, Meitheal Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for a new injectable drug, Phosphomycin, 6 g/vial, aimed at treating complex urinary tract infections, including acute pyelonephritis, and inhibiting the development of diseases caused by resistant bacteria [1]. Group 1 - The FDA approval is for Phosphomycin, which is indicated for the treatment of complex urinary tract infections [1]. - The drug is specifically designed to address acute pyelonephritis and combat antibiotic-resistant bacteria [1].

格隆汇10月24日丨健友股份(603707.SH)公布，公司第三季度实现营业收入9.46亿元，同比增长0.06%； 归属于上市公司股东的净利润1.43亿元，同比下降28.67%；归属于上市公司股东的扣除非经常性损益的 净利润1.24亿元，同比下降30.95%；基本每股收益0.09元。 ...

南京健友生化制药股份有限公司 董事会议事规则 第一条 宗旨 为了进一步明确南京健友生化制药股份有限公司（简称"公司"）董事会 的职责权限、规范公司董事会的议事方式和决策程序，促使董事和董事会有效 地履行其职责，提高董事会规范运作和科学决策水平，根据《公司法》、《证 券法》等有关规定和公司章程，制订本规则。 第二条 董事会办公室 董事会下设董事会办公室，处理董事会日常事务。 董事会秘书兼任董事会办公室负责人，保管董事会和董事会办公室印章。 第三条 定期会议 董事会会议分为定期会议和临时会议。 董事会每年应当至少在上下两个半年度各召开一次定期会议。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，董事会办公室应当充分征求各董事 的意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总经理和其他高级管理人员的意 见。 第五条 临时会议 有下列情形之一的，董事会应当召开临时会议： （一）代表十分之一以上表决权的股东提议时； 1 第六条 临时会议的提议程序 按照前条规定提议召开董事会临时会议的，应当通过董事会办公室或者直 接向董事长提交经提议人签字（盖章）的书面提议。书面提议中应当载明下 ...

南京健友生化制药股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事，下同）及高 级管理人员的考核和薪酬管理制度，完善公司治理结构，根据《公司 法》、公司章程及其他有关规定，公司董事会设薪酬与考核委员会， 并制订本工作细则。 第四条 薪酬与考核委员会委员由董事长、二分之一以上独立董 事或者三分之一以上全体董事提名，并由董事会选举产生。 第二章 人员组成 第三条 薪酬与考核委员会成员由 3 名董事组成，其中独立董事 2 名。 第六条 薪酬与考核委员会任期与董事会任期一致，委员任期届 满，连选可以连任。期间如有委员不再担任公司董事职务，自动失去 1 委员资格，并由委员会依据本工作细则第三至第五条规定补足委员人 数。 第七条 薪酬与考核委员会下设薪酬与考核委员会工作小组，为 薪酬与考核委员会日常工作机构，专门负责提供公司有关经营方面的 资料及被考评人员的有关资料，负责筹备薪酬与考核委员会会议并执 行薪酬与考核委员会的有关决议。 第三章 职责权限 第八条 薪酬与考核委员会负责制定董事、高级管理人员的考核 标准并进行考核，制定、审查董事、高级管理人员的薪酬决定机制、 ...

南京健友生化制药股份有限公司 防范大股东及其关联方资金占用制度 第一条 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司监管指引第8号——上市公司资金往来、对外担保的监管要求》、 《上海证券交易所上市公司自律监管指引第1号——规范运作》等有 关法律、法规规范性文件的要求以及《南京健友生化制药股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，为防止大股东 及其关联方占用上市公司资金行为，进一步维护公司全体股东和债权 人的合法权益，建立起南京健友生化制药股份有限公司（以下简称 "公司"或"本公司"）防范大股东及其关联方占用公司资金的长效 机制，杜绝大股东及其关联方资金占用行为的发生，特制定本制度。 第二条 本制度所称资金占用包括但不限于：经营性资金占用和 非经营性资金占用。经营性资金占用是指控股股东及其关联方通过采 购、销售等生产经营环节的关联交易产生的资金占用；非经营性资金 占用是指代控股股东及其关联方垫付工资、福利、保险、广告等费用 和其他支出，代控股股东及其关联方偿还债务而支付资金，有偿或无 偿、直接或间接拆借给控股股东及其 ...

南京健友生化制药股份有限公司 章 程 二〇二五年十月 | 第一章 总 则 . | | --- | | 第二章 经营宗旨和范围 | | 第一节 股份发行 . | | 第二节 股份增减和回购 | | 第三节 股份转让 . | | 第四章 股东和股东会 . | | 第一节 股东的一般规定 | | 第二节 控股股东和实际控制人 . | | 第三节 股东会的一般规定 | | 第四节 股东会的召集 . | | 第五节 股东会的提案与通知 | | 第六节 股东会的召开 . | | 第七节 股东会的表决和决议 21 | | 第五章 董事和董事会 | | 第一节 董事的一般规定 | | 第二节 董事会 . | | 第三节 独立董事 . | | 第四节 董事会专门委员会 | | 第六章 总经理及其他高级管理人员 . | | 第七章 财务会计制度、利润分配和审计 . | | 第一节 财务会计制度 · | | 第二节 内部审计 . | | --- | | 第三节 会计师事务所的聘任 | | 第八章 通知和公告 | | 第九章 合并、分立、增资、减资、解散和清算 50 | | 第一节 合并、分立、增资和减资 | | 第二节 解散和清算 ...